INTRODUCTION: The aim of this study was to determine if correlations exist between quantitative parameters from dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI with National Comprehensive Cancer Network (NCCN) risk group, Gleason score (GS), maximum tumour diameter (MTD), pre-treatment prostate-specific antigen (PSA), clinical T stage and MRI prostate volume in prostate cancer. METHOD: We retrospectively reviewed 3T multiparametric MRI reports on biopsy-proven prostate cancer patients performed during radiation treatment evaluation or an active surveillance protocol. DCE-MRI parameters included K(trans) (influx volume transfer coefficient), Kep (efflux reflux rate constant) and iAUC (initial area under the curve). Average DCE and apparent diffusion coefficient (ADC) values were recorded for regions of interest on DW-MRI. Relationships between MRI metrics and risk group, GS, MTD, PSA, clinical T stage and MRI prostate volume were examined using analysis of variance. Central and peripheral tumours were also analysed separately in a sub-analysis. Statistical significance was defined as P < 0.0125. RESULTS: Of 58 patients, 29%, 52% and 19% had low (L), intermediate (I), or high (H) NCCN risk disease, respectively. K(trans) significantly correlated with PSA. For central tumours, K(trans) significantly correlated with MTD and PSA, and Kep significantly correlated with PSA. For peripheral tumours, iAUC was significantly different when stratified by L/I/H risk and GS, and ADC score with L/I/H risk, GS, and clinical T stage. CONCLUSIONS: DCE- and DW-MRI metrics correlate with some risk stratification factors in prostate cancer. Further work is required to determine if MRI metrics are complementary or independent prognostic factors.
INTRODUCTION: The aim of this study was to determine if correlations exist between quantitative parameters from dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI with National Comprehensive Cancer Network (NCCN) risk group, Gleason score (GS), maximum tumour diameter (MTD), pre-treatment prostate-specific antigen (PSA), clinical T stage and MRI prostate volume in prostate cancer. METHOD: We retrospectively reviewed 3T multiparametric MRI reports on biopsy-proven prostate cancerpatients performed during radiation treatment evaluation or an active surveillance protocol. DCE-MRI parameters included K(trans) (influx volume transfer coefficient), Kep (efflux reflux rate constant) and iAUC (initial area under the curve). Average DCE and apparent diffusion coefficient (ADC) values were recorded for regions of interest on DW-MRI. Relationships between MRI metrics and risk group, GS, MTD, PSA, clinical T stage and MRI prostate volume were examined using analysis of variance. Central and peripheral tumours were also analysed separately in a sub-analysis. Statistical significance was defined as P < 0.0125. RESULTS: Of 58 patients, 29%, 52% and 19% had low (L), intermediate (I), or high (H) NCCN risk disease, respectively. K(trans) significantly correlated with PSA. For central tumours, K(trans) significantly correlated with MTD and PSA, and Kep significantly correlated with PSA. For peripheral tumours, iAUC was significantly different when stratified by L/I/H risk and GS, and ADC score with L/I/H risk, GS, and clinical T stage. CONCLUSIONS:DCE- and DW-MRI metrics correlate with some risk stratification factors in prostate cancer. Further work is required to determine if MRI metrics are complementary or independent prognostic factors.
Authors: Stephanie L Barnes; Anna G Sorace; Mary E Loveless; Jennifer G Whisenant; Thomas E Yankeelov Journal: NMR Biomed Date: 2015-08-30 Impact factor: 4.044